Integra Lifesciences Holdings (IART) Cash from Investing Activities (2009 - 2026)

Integra Lifesciences Holdings has disclosed Cash from Investing Activities across 18 years of filings, most recently posting -$43.3 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 99.94% year-over-year to -$43.3 million; the TTM figure through Jun 2026 stood at -$108.6 million (down 50.42% YoY), while the FY2025 annual figure was -$108.1 million, up 72.35% from the prior year.
• Cash from Investing Activities came in at -$43.3 million for Q2 2026 at Integra Lifesciences Holdings, down from -$14.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $14.8 million in Q3 2022 to a low of -$322.2 million in Q2 2024.
• Average Cash from Investing Activities over 5 years is -$39.4 million, with a median of -$15.6 million recorded in 2023.
• Year-over-year, Cash from Investing Activities soared 274.69% in 2022 and sank 1972.28% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$54.8 million in 2022, then fell by 4.39% to -$57.2 million in 2023, then surged by 92.58% to -$4.2 million in 2024, then plunged by 721.53% to -$34.9 million in 2025, then declined by 24.0% to -$43.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$43.3 million in Q2 2026, -$14.8 million in Q1 2026, and -$34.9 million in Q4 2025.